You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Drugs in MeSH Category Anesthetics, Dissociative


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations KETALAR ketamine hydrochloride INJECTABLE;INJECTION 016812-002 Approved Prior to Jan 1, 1982 AP RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Gland KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 216809-002 Jan 24, 2023 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Fresenius Kabi Usa KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 215808-001 Jan 13, 2023 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Eugia Pharma KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 076092-002 Dec 28, 2001 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Eugia Pharma KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 076092-003 Oct 25, 2002 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Endo Operations KETALAR ketamine hydrochloride INJECTABLE;INJECTION 016812-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Anesthetics, Dissociative Market Analysis and Financial Projection

Last updated: March 24, 2025

The market dynamics for dissociative anesthetics like ketamine and esketamine are marked by rapid growth driven by expanding therapeutic applications, while the patent landscape faces challenges over monopolization and ethical concerns regarding biopiracy.

Market Dynamics

  • Projected Growth:

    • The global anesthesia drugs market is expected to grow at a 3.3% CAGR, reaching $9.4 billion by 2033 [15]. Dissociative anesthetics contribute significantly, with ketamine leading due to its dual use in anesthesia and mental health.
    • The ketamine treatment market is growing exponentially at a 42.35% CAGR, projected to reach $5.18 billion by 2030, fueled by its off-label use for treatment-resistant depression (TRD), PTSD, and chronic pain [17].
    • Esketamine (a ketamine derivative) is a key driver, with its market forecasted to hit $2.2 billion by 2030 due to FDA approval for TRD and nasal spray formulations [16].
  • Therapeutic Expansion:

    • Ketamine’s mechanism—NMDA receptor antagonism—has spurred research into glutamate modulation for depression, with studies showing dissociation and analgesia can be separated, enabling targeted therapies [5][12].
    • 65% of sales for dissociative anesthetics target non-retail settings (e.g., hospitals), while 17% are retail prescriptions, reflecting increased accessibility for mental health applications [9][15].

Patent Landscape and Challenges

  • Monopolization Risks:

    • Companies like Compass Pathfinder and Janssen Biotech (maker of Spravato®) use patent thickets to dominate markets, filing overlapping patents on formulations (e.g., crystalline psilocybin) or administration methods (e.g., therapy settings) [2][10].
    • Ketamine’s generic status has led to "supergeneric" innovations like Abraxane® (nanoparticle albumin-bound paclitaxel) to extend patent life [3][12].
  • Ethical and Legal Issues:

    • Biopiracy concerns arise when patents fail to acknowledge Indigenous knowledge, such as traditional uses of psychedelics in healing practices [2][10].
    • The U.S. Patent Office’s lack of expertise in psychedelic history has led to controversial patents, including methods for “muted room settings” during therapy, which critics argue lack novelty [2][10].
  • Innovation vs. Access:

    • Patent pledges and prior art repositories are proposed to prevent unwarranted patents, but adoption remains limited [2][10].
    • Esketamine’s FDA breakthrough designation accelerated approval but raised costs, with treatment courses exceeding $6,000, limiting accessibility despite efficacy [12][16].

Future Outlook

  • Regulatory and Research Trends:
    • Psychedelic therapy startups are bypassing patents via telehealth models and derivative drugs (e.g., arketamine) to avoid litigation [12].
    • NMDA-targeting peptides (e.g., ProTx-II) and glutamatergic drugs are under development to improve specificity and reduce side effects [6].
Factor Impact
Generic Competition Reduces prices but incentivizes supergenerics (e.g., nasal sprays) [3][12]
FDA Designations Accelerate approvals but prioritize branded drugs over generics [12][16]
Patent Litigation Risks Deter small firms from entering the market [2][10]

"The dissociative properties of ketamine have opened new pathways in mental health treatment, yet patent strategies risk stifling the very innovation they aim to protect." [10][12]

This landscape highlights a tension between therapeutic potential and intellectual property challenges, requiring balanced policies to ensure equitable access and continued innovation.

References

  1. https://adf.org.au/drug-facts/dissociatives/
  2. https://harvardlawreview.org/forum/no-volume/patents-on-psychedelics-the-next-legal-battlefront-of-drug-development/
  3. https://www.ufrgs.br/imunovet/molecular_immunology/anticancer.html
  4. https://www.lahacienda.com/dissociative-anesthetics
  5. https://journals.lww.com/painrpts/fulltext/2021/07000/dissociative_and_analgesic_properties_of_ketamine.7.aspx
  6. https://elifesciences.org/reviewed-preprints/81727
  7. https://jamanetwork.com/journals/jama/fullarticle/360140
  8. https://patents.google.com/patent/WO2004103260A2/en
  9. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM628319.pdf
  10. https://ir.law.fsu.edu/cgi/viewcontent.cgi?article=1738&context=articles
  11. https://www.bjmp.org/category/content/review-article?if=1
  12. https://btlj.org/wp-content/uploads/2024/05/0004_39-LSI_Joralemon.pdf
  13. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs-medicines
  14. https://meshb-prev.nlm.nih.gov/record/ui?ui=D000778
  15. https://media.market.us/ketamine-statistics/
  16. https://www.globenewswire.com/news-release/2023/09/21/2747317/0/en/Latest-Esketamine-Market-Analysis-Consumption-Patterns-Trends-Growth-Opportunities-Forecast-2023-2030.html
  17. https://www.maximizemarketresearch.com/market-report/ketamine-treatment-market/216827/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.